The efficacy benefits of TACE with PD-(L)1 inhibitors plus MTT were generally consistent across clinical subgroups, including those of relevance to HCC (ECOG performance status, HBV etiology, baseline tumor burden, and the with or without macrovascular invasion and/or extrahepatic spread). This evidence concerns the gene CD274 and hepatocellular carcinoma.